CTI BioPharma And Baxter International Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At European Hematology Association

Press/Media: Press / Media

PeriodJun 10 2015

Media coverage

1

Media coverage

  • TitleCTI BioPharma And Baxter International Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At European Hematology Association
    Media name/outletBioSpace
    CountryUnited States
    Date6/10/15
    PersonsRuben Mesa